Skip to content
10-K

Annual Report

AVANIR PHARMACEUTICALS, INC.

0001193125-14-439125

← back to feed
Filed
Dec 10, 2014 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2014 · Dec 1, 2014 193.76M sh
Capex FY 2014 · Sep 30, 2014 $3.06M
Capex restated FY 2014 · Sep 30, 2013 $449K
Capex restated FY 2014 · Sep 30, 2012 $813K
Cash And Equivalents FY 2014 · Sep 30, 2014 $271.87M
Cash And Equivalents restated FY 2014 · Sep 30, 2013 $55.26M
Cash And Equivalents restated FY 2014 · Sep 30, 2012 $69.78M
Cash And Equivalents restated FY 2014 · Sep 30, 2011 $79.54M
Stockholders Equity FY 2014 · Sep 30, 2014 $273.39M
Stockholders Equity restated FY 2014 · Sep 30, 2013 $18.47M
Stockholders Equity restated FY 2014 · Sep 30, 2012 $36.84M
Stockholders Equity restated FY 2014 · Sep 30, 2011 $71.34M
Current Liabilities FY 2014 · Sep 30, 2014 $32.09M
Current Liabilities restated FY 2014 · Sep 30, 2013 $34.79M
Total Liabilities FY 2014 · Sep 30, 2014 $33.59M
Total Liabilities restated FY 2014 · Sep 30, 2013 $57.61M
Current Assets FY 2014 · Sep 30, 2014 $300.82M
Current Assets restated FY 2014 · Sep 30, 2013 $71.84M
Total Assets FY 2014 · Sep 30, 2014 $306.98M
Total Assets restated FY 2014 · Sep 30, 2013 $76.08M
Rd Expense FY 2014 · Sep 30, 2014 $44M
Rd Expense restated FY 2014 · Sep 30, 2013 $49.51M
Rd Expense restated FY 2014 · Sep 30, 2012 $23.07M
Net Income FY 2014 · Sep 30, 2014 −$50.44M
Net Income restated FY 2014 · Sep 30, 2013 −$75.48M
Net Income restated FY 2014 · Sep 30, 2012 −$59.74M
Operating Income FY 2014 · Sep 30, 2014 −$46.34M
Operating Income restated FY 2014 · Sep 30, 2013 −$71.43M
Operating Income restated FY 2014 · Sep 30, 2012 −$58.4M
Cost Of Revenue FY 2014 · Sep 30, 2014 $3.32M
Cost Of Revenue restated FY 2014 · Sep 30, 2013 $4M
Cost Of Revenue restated FY 2014 · Sep 30, 2012 $2.12M
Revenue FY 2014 · Sep 30, 2014 $115.03M
Revenue restated FY 2014 · Sep 30, 2013 $75.37M
Revenue restated FY 2014 · Sep 30, 2012 $41.28M
Stock Issued FY 2014 · Sep 30, 2012 12.36M sh
Stock Issued restated FY 2014 · Sep 30, 2012 3.67M sh